| Valuation method | Value, € | Upside, % |
|---|---|---|
| Artificial intelligence (AI) | 27.88 | 38622 |
| Intrinsic value (DCF) | 85.60 | 118789 |
| Graham-Dodd Method | n/a | |
| Graham Formula | n/a |
TME Pharma N.V. (ALTME.PA) is a clinical-stage biopharmaceutical company headquartered in Berlin, Germany, specializing in the development of innovative cancer therapies. Leveraging its proprietary Spiegelmer platform, TME Pharma focuses on novel treatments for aggressive cancers, including metastatic pancreatic and colorectal cancer, glioblastoma, and myeloma. Its lead candidate, NOX-A12, is being developed as a combination therapy, with a notable collaboration with Merck Sharp & Dohme Corp. to evaluate its efficacy alongside Keytruda and chemotherapy in pancreatic cancer. The company also has NOX-E36, a candidate for diabetic nephropathy, which has completed Phase 1/2 trials. Formerly known as NOXXON Pharma N.V., the company rebranded in 2022 to reflect its focus on tumor microenvironment (TME) modulation. With a market cap of approximately €7.3 million, TME Pharma operates in the high-risk, high-reward biotechnology sector, targeting unmet medical needs in oncology.
TME Pharma presents a high-risk, high-reward investment opportunity due to its clinical-stage pipeline and focus on oncology. The company has no current revenue, reporting a net loss of €5.7 million in its latest fiscal period, with negative operating cash flow. However, its collaboration with Merck Sharp & Dohme Corp. provides validation for its NOX-A12 candidate. Investors should note the speculative nature of biotech investments, particularly given TME Pharma’s early-stage assets and reliance on clinical trial success. The company’s cash position (€2.2 million) and modest debt (€1.2 million) suggest limited near-term liquidity concerns, but further capital raises may be necessary to fund ongoing trials. The stock’s high beta (1.503) indicates significant volatility, making it suitable only for risk-tolerant investors.
TME Pharma competes in the highly competitive oncology biotech space, where differentiation hinges on novel mechanisms of action and clinical efficacy. Its Spiegelmer platform offers a unique approach by targeting the tumor microenvironment (TME), potentially improving drug delivery and immune response modulation. However, the company faces intense competition from larger biopharma firms with deeper pipelines and greater financial resources. TME Pharma’s collaboration with Merck Sharp & Dohme Corp. is a strategic advantage, providing access to Keytruda, a leading immunotherapy. Yet, the company’s reliance on a single lead candidate (NOX-A12) increases risk if clinical trials fail. Competitors with broader oncology portfolios, such as Roche and Bristol-Myers Squibb, dominate the market, making it challenging for smaller players like TME Pharma to secure market share. Success will depend on demonstrating superior efficacy in niche indications where larger players are less active.